Get the Stockscreener App
6.55
1.71%
+0.11
After Hours:
6.62
0.07
+1.07%
Adma Biologics Inc stock is currently priced at $6.55, with a 24-hour trading volume of 1.54M.
It has seen a +1.71% increased in the last 24 hours and a +0.77% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.40 pivot point. If it approaches the $6.62 resistance level, significant changes may occur.
Previous Close:
$6.44
Open:
$6.47
24h Volume:
1.54M
Market Cap:
$1.52B
Revenue:
$258.22M
Net Income/Loss:
$-28.24M
P/E Ratio:
-32.75
EPS:
-0.2
Net Cash Flow:
$3.82M
1W Performance:
+4.47%
1M Performance:
+0.77%
6M Performance:
+99.70%
1Y Performance:
+98.48%
1D Range:
$6.40
$6.60
52W Range:
$3.06
$6.76
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
201-478-5552
Address
465 State Route 17, Ramsey
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks Investment Research
Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know
Zacks Investment Research
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks Investment Research
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Zacks Investment Research
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks Investment Research
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks Investment Research
Adma Biologics Inc Stock (ADMA) Financials Data
Adma Biologics Inc (ADMA) Revenue 2024
ADMA reported a revenue (TTM) of $258.21 million for the quarter ending December 31, 2023, a +67.59% rise year-over-year.
Adma Biologics Inc (ADMA) Net Income 2024
ADMA net income (TTM) was -$28.24 million for the quarter ending December 31, 2023, a +57.15% increase year-over-year.
Adma Biologics Inc (ADMA) Cash Flow 2024
ADMA recorded a free cash flow (TTM) of $3.82 million for the quarter ending December 31, 2023, a +105.20% increase year-over-year.
Adma Biologics Inc (ADMA) Earnings per Share 2024
ADMA earnings per share (TTM) was -$0.13 for the quarter ending December 31, 2023, a +61.76% growth year-over-year.
About Adma Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
1.53%
3.38%
Cap:
|
Volume (24h):